Objective: To study the influence of laser combined with Conbercept therapy on serum cytokines and oxidation products in patients with diabetic retinopathy (DR). Methods: 118 cases of DR patients who were treated in our hospital between June 2014 and January 2017 were collected and retrospectively divided into the control group (n=60) who underwent laser therapy alone and the observation group (n=58) who underwent laser combined with Conbercept therapy. Serum contents of angiogenesis-related

more »

... icators, inflammatory factors, oxidative metabolites and others were compared between two groups of patients before and after treatment. Results: Before treatment, differences in serum contents of angiogenesisrelated indicators, inflammatory factors and oxidative metabolites were not statistically significant between two groups of patients. After treatment, serum contents of angiogenesisrelated indexes IGF-1, VEGF, EPO, TGF-β and bFGF in observation group were lower than those in control group; contents of inflammatory factors IL-1β, IL-6 and IL-8 were lower than those in control group; contents of oxidative metabolites MDA, AOPPs, LHP and ROS were lower than those in control group. Conclusion: Laser combined with Conbercept therapy can effectively inhibit ocular angiogenesis and reduce systemic inflammation and oxidative stress in patients with DR.